Rupee Swings Reshape Deals: Bullish for TCS, INFY; Risk for Importers

Rupee volatility has emerged as a decisive variable in India's distressed deal market, pressuring otherwise stable firms carrying dollar-denominated debt. Hedging costs have risen, and FX uncertainty is forcing renegotiation of deal pricing, structures, and timelines.

Beyond M&A, this signals a broader market preference for businesses with natural USD hedges, which has implications for sector allocation. Companies with export revenue or dollar receivables are being repriced higher relative to import-heavy or dollar-leveraged peers, a theme that persists as long as INR remains volatile.

Export-linked names like TCS, INFY, HCLTECH, SUNPHARMA, and DRREDDY benefit from natural hedges and investor rotation. Conversely, OMCs (IOC, BPCL) and corporates with large unhedged ECBs face margin and refinancing pressure. Adani group names with dollar debt remain in focus given mixed export-import exposure.

Watch USDINR levels, RBI's FX intervention pattern, and forward premia trends. Track Q1FY27 commentary from IT/pharma on hedge gains and from OMCs/infra on FX losses; any sharp INR move beyond 84-85 could trigger fresh stress in leveraged names.

• •Rupee volatility is central to India's distressed deals
• •Firms with dollar debt face stress despite stable operations
• •Elevated hedging costs are reshaping deal pricing and timelines
• •Investors favoring export-linked assets and natural hedges